S_q In this single-centre study of 881 patients, S-phase fraction (SPF) was shown to be a sgnifiant prognostic marker in terms of ovrll suvival (OS), rdapse-free survival (RFS) A further stimulus to publish our data came from two recent reports which failed to find a prognostic role for SPF in breast cancer (Stanton et al., 1992; Silvestini et al., 1993 
Measures of prolferative activity in breast carcinoma have been shown to be of prognostic value in a large number of published studis. The techniques used to assess proliferative activity have included mitotic index (Eelinen et al., 1992) , I3Hlthynidine labelling index (Sivestrini et al., 1993) , a variety of immunohistochemical methods involving antibodies such as Ki-67 (Bouzubar et al., 1989) and DNA flow cytometry.
Although there are numerous papers on flow cytometry in breast cancer, many of these involve fewer than 200 patients (for reviews see Merkel and McGuire, 1990; Hedley et al., 1993) . Large single-centre data sets, involving 500 patients or more, with long-term follow-up and information on other prognostic factors, and in paricular tumour grade, have rarely been reported. Such large data sets are clarly required if the prognostic value of SPF/ploidy is to be ckarly understood, quantified and compared with other known prognostic factors. We have therefore combied the information from several previous smaller data sets from this hospital for the purpose of this report.
The reviews of flow cytometry and the vast majority of published studies in which S-phase fraction (SPF) has been measured support the view that this proliferation-related parameter is a strong prognostic indicator in mammary carcinoma. The evience for DNA ploidy as a prognostic marker, particularly one independent of other clinicopathological variables, is less convinmcng.
In this report we have brought together all the data from several alr studies from Guy's Hospital which have examined the potential usefulness of ploidy and SPF measurenmets m different clinical situations. These studies inclue an unselcted group of patiets with operable breast cancer (O'Reilly, 1990a) , a group of patients with nodenegative diseas (O'Reilly, 1990b ) and a group of nodepositive patients treated in an adjuvant chemotherapy study compring CMF (cydophosphamide, methotrexate, 5-fuorouracil) with controls (O'Reilly, 1990c) . Further tumour samples were studied for comparison of flow cytometric parameters with other tumour characteristics such as histological grade (Masters et al., 1987) and c-erb-B-2 expression (Banes et al., 1992) or for analysis of the effects of different fixation methods on flow cytometric analyses (Gilkett et al., 1990) . These A further stimulus to publish our data came from two recent reports which failed to find a prognostic role for SPF in breast cancer (Stanton et al., 1992; Silvestini et al., 1993 outcome. The mean age of the patients was 55.9 (range 21-94) years. The study group included a larger number of patients with ten or more axiflary lymph nodes and a smaller number of patients presenting with locally advanced/ metastatic disease than is observed for al patients treated at this centre (Table I ). This was due to the selection of material for the separate smaller studies (see Introduction). However, the overall outcome for the 881 patients studied was very similar to that of the total patient population (Figure 1 ).
Adjuvant therapy In general, adjuvant therapy was given in the context of a series of randomised controLld trials and was given almost exclusively to node-positive patients until 1989. These studies included comparisons of meiphalan (Rubens et al., 1983) , CMF (Richards et al., 1990) and tamoxifen (Singh et al., 1988) (Camplejohn et al., 1989; Camplejohn, 1992) . Briefly, SOpm sections were dewaxed and taken to 50% alcohol overnight using a Histokinette tissue-processing machine. Tbe sections were then rinsed in distilled water and incubated in 0.5% pepsin solution at pH 1.5 and 37C for 30min. Released nucli were spun, washed and debris removed by filtration through a 35 pm nylon gauze filter. Nuclei were stained with a DNAspecific dye, 4',6'-diamidino-2-phenyindole-dihydrochloride (DAPI) at a concentration of I pg ml-'. We had previously shown that results obtained with DAPI are similar to those obtained with the more commonly used DNA fluorocbrome propidium iodide (Camplejohn et al., 1989 Camplejohn (1992 Figure 3 .
Relapse-free survival . aneuploid (n = 496). Effect of adjuvant therapy Adjuvant chemotherapy was negatively correlated with survival on univanate analysis. This is a result of the patient selection policy, as previously described, with adjuvant chemotherapy being given almost exclusively to node positive premenopausal patients. The adjuvant chemotherapy patients thus appear to fare poorly simply because they are, in the main, node positive. The few node-negative patients who were given adjuvant chemotherapy (n = 36) were more likely to be grade III, exacerbating this effect (these patients were not from randomised trials, in contrast to the node-positive patients Based on the various studies from this centre related to tumour grade and SPF measurements, clinical practice in relation to the use of adjuvant therapy has been altered, particularly amongst node-negative patients (O'Reilly, 1990b; O'Reilly and Richards, 1990) . High-risk node-negative patients are identified for adjuvant therapy by a combination of tumour size and either grade III or high SPF. We are also planning to undertake a study of intensive adjuvant chemotherapy in patients with four or more involved lymph nodes. Those with grade I or low SPF tumours will, however, be excluded. independent prognostic power in the multivanate analyss despite its association with SPF. Earlier reports from our group failed to demonstrate this relationship even in a univariate analysis (O'Reilly et al., 1990a-c) , though all these studies had shown a trend for DNA aneuploidy to signify a poorer prognosis. Further, the results of the present study are in ine with the overview from the literature in that, while DNA ploidy is significntly ted to cinical outcome, the magnitude of the survival advantage of a DNA diploid tumour over an aneuploid one is small (Camplejohn and Macartney, 1992; Hedley et al., 1993 (Ferrero et al., 1990) . Either method of removing normal cells from the analysis of SPF for DNA diploid tumours would be expected to improve further the prognostic power of this parameter.
A particular point of interest to us has been the nature of the assoation between tumour grade and SPF. As repoted in our earler studi (O'Reilly et al., 1990a-c) and by many others (Merkel and McGuire, 1990; Hedley et al., 1993) , there is a strong association bten these two parametr. In our earlier, smaller stude it was not possible to demonstrate an indepedent prognostic power for SPF when tumour grade was included in the multivariate analysis. In this larger cohort of patients, such an independent prognostic ability for SPF could be demonstrated and the x2 value for SPF (26.7) was higher than that for tumour grade (21.9). In the ICRF Clinical Oncology Unit at Guy's Hospital tumour grading is given a high priority and is performed in a histopathology laboratory dicted to the study of breast lesions; under these circumstances tumour grade has always shown a strong association with clinical outcome. In other studies, however, tumour grade has not been a useful prognostic marker (Brooks et al., 1993) . In all of these studies ther has consistently been a strong association between SPF and clnical outcome. The relative merits of tumour grade and SPF as prognostic markers clerly depend on the quality of each asseent, but the present large study suggests that SPF is at kast as good as tumour grade in predicting clinical outcome for those tumours for which SPF is available.
It is quite often claimed that DNA flow cytometry is unsuitable as a routine method because of the cost of the equipment required. However, in preparing a putative budget for performing DNA flow cytometry on all new cases of breast cancer'in the South-East Thames Region some years ago, we found that the cost per sample was not overly expensive when mesurmets were performed in a single central facility (Campkjohn, 1993) . The main practical disadvantage of DNA flow cytometry in breast cancer would seem to be the inability to obtain SPF data on around 25% of patiets presentng. Some of the faires are due to the inability to obtain good DNA histograms, and the magnitude of this problem might be reduced by modifications to fixation procedures for praffin-embedded samples (Gillett et al., 1990) or by the use of fine-needle aspiration of unfixed tissue to obtain material for flow cytometry (Vindelov and Christensen, 1990 ). However, the majority of cases which fail to yield SPF data are the result of probiems in cculating SPF caused by factors such as DNA multiploidy, diploid and aneuploid GI peaks being too close together or very small aneupnoid peaks. It is possible that modern computer programs available now might improve this situation somewhat (Hedley et al., 1993) , but it seems hikely that there will always be a sinficant minority of cases for which an SPF value cannot be alclated.
Recent matatical models (Gregory et al., 1991) suggest that when a factor correlates with tumour growth rate the relaps-free surival curves should show different slopes (steeper slopes for faster growing tumours). This can be seen with the SPF curves shown in this study (the relapse-free survival curves are similar to the survival curves shown in Figure 2 ), confirming a correlation with the growth rate of the tumour. Since the effect of chemotherapy is thought to be greatest for rapidly dividng tumours, this supports the policy of usng SPF to select patients for adjuvant chemotherapy.
From the data in this study and the consensus revew of the literature (Hedley et al., 1993) , it is ckar that SPF is a powerful prognostic indicator in breast cancer. In common with the measurement of all present proliferative marers, SPF measurement suffers from some drawbacks, for example the inability to assess SPF in multiploid cases. However, it wes to have potential for defining subgroups for which approprate treatments can be seected. For example, it may have a particular role in defining those patients with nodenegative diseas who require adjuvant systemic therapy (Toikkanen et al., 1989; O'Reilly et a,, 199; Sigurdon et al., 1990 
